Overview

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.

Phase:

PHASE2

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

130-nm albumin-bound paclitaxel
Capecitabine
eribulin